Teva Hits Back In Gilead Patent Suit Over HIV Drug
On Friday, Teva filed a second amended answer and counterclaim to the suit Gilead brought against the company in the U.S. District Court for the Southern District of New York.
In a second amended complaint, Gilead accused Teva of infringing patents for Truvada, tablets containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate, and for Atripla, which is...
Already a subscriber? Click here to login